SCHEMBL31557707

N=C(N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 12)

	gene	UniProt	supporting neighbours	confidence
▸	SLC15A2	Q16348	1/20	0.42

▸	NMT2	O60551	2/20	0.40

▸	NMT1	P30419	2/20	0.40

▸	FOLH1	Q04609	1/20	0.39

▸	NPY4R	P50391	3/20	0.39

▸	NPY1R	P25929	2/20	0.39

▸	NPY2R	P49146	2/20	0.39

▸	NPY5R	Q15761	2/20	0.39

▸	IL23R	Q5VWK5	7/20	0.38

▸	OPRM1	P35372	1/20	0.38

▸	TLR2	O60603	1/20	0.38

▸	ROCK2	O75116	1/20	0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29614393	0.94	SLC15A2 (0.47)	SLC15A2NMT2NMT1FOLH1NPY4R
SCHEMBL29920863	0.94	SLC15A2 (0.47)	SLC15A2NMT2NMT1FOLH1NPY4R
SCHEMBL29712681	0.94	SLC15A2 (0.47)	SLC15A2NMT2NMT1FOLH1NPY4R
SCHEMBL29736266	0.94	SLC15A2 (0.47)	SLC15A2NMT2NMT1FOLH1NPY4R
SCHEMBL30562993	0.94	SLC15A2 (0.47)	SLC15A2NMT2NMT1FOLH1NPY4R
SCHEMBL29534033	0.90	NPY4R (0.41)	SLC15A2NPY4RNPY1RNPY2RNPY5R
SCHEMBL29375065	0.90	NPY4R (0.44)	NMT2NMT1FOLH1NPY4RNPY1R
SCHEMBL29482452	0.89	NPY4R (0.43)	SLC15A2FOLH1NPY4RNPY1RNPY2R
SCHEMBL30120973	0.89	NPY4R (0.43)	SLC15A2FOLH1NPY4RNPY1RNPY2R
SCHEMBL31589811	0.88	TLR2 (0.47)	NMT2NMT1NPY4RNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-119907678-A	Medicaments (variants) for combining gene-directed enzyme prodrug therapy with immunotherapy for the treatment of solid malignancies	吉那亚希鲁尔吉亚有限责任公司	2025-04-29	—	—	CN	disclosed